These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

247 related articles for article (PubMed ID: 23688863)

  • 1. Emergence of antiviral resistance during oral valganciclovir treatment of an infant with congenital cytomegalovirus (CMV) infection.
    Choi KY; Sharon B; Balfour HH; Belani K; Pozos TC; Schleiss MR
    J Clin Virol; 2013 Aug; 57(4):356-60. PubMed ID: 23688863
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect on hearing of oral valganciclovir for asymptomatic congenital cytomegalovirus infection.
    Yilmaz Çiftdogan D; Vardar F
    J Trop Pediatr; 2011 Apr; 57(2):132-4. PubMed ID: 20576693
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Multiple ganciclovir-resistant strains in a newborn with symptomatic congenital human cytomegalovirus infection.
    Campanini G; Zavattoni M; Cristina E; Gazzolo D; Stronati M; Baldanti F
    J Clin Virol; 2012 May; 54(1):86-8. PubMed ID: 22381918
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Successful valganciclovir treatment of post-transplant cytomegalovirus infection in the presence of UL97 mutation N597D.
    Iwasenko JM; Scott GM; Rawlinson WD; Keogh A; Mitchell D; Chou S
    J Med Virol; 2009 Mar; 81(3):507-10. PubMed ID: 19152402
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment of symptomatic congenital cytomegalovirus infection with valganciclovir.
    Meine Jansen CF; Toet MC; Rademaker CM; Ververs TF; Gerards LJ; van Loon AM
    J Perinat Med; 2005; 33(4):364-6. PubMed ID: 16211780
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cytomegalovirus resistance in solid organ transplant recipients treated with intravenous ganciclovir or oral valganciclovir.
    Boivin G; Goyette N; Rollag H; Jardine AG; Pescovitz MD; Asberg A; Ives J; Hartmann A; Humar A
    Antivir Ther; 2009; 14(5):697-704. PubMed ID: 19704173
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetics, pharmacodynamics and clinical use of valganciclovir in newborns with symptomatic congenital cytomegalovirus infection.
    Stronati M; Lombardi G; Garofoli F; Villani P; Regazzi M
    Curr Drug Metab; 2013 Feb; 14(2):208-15. PubMed ID: 22935067
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Incidence and characterization of cytomegalovirus resistance mutations among pediatric solid organ transplant patients who received valganciclovir prophylaxis.
    Martin M; Goyette N; Ives J; Boivin G
    J Clin Virol; 2010 Apr; 47(4):321-4. PubMed ID: 20138805
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Onset of valganciclovir resistance in two infants with congenital cytomegalovirus infection.
    Garofoli F; Lombardi G; Angelini M; Campanini G; Zavattoni M; Baldanti F
    Int J Infect Dis; 2020 Sep; 98():150-152. PubMed ID: 32615325
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Viral load in children with congenital cytomegalovirus infection identified on newborn hearing screening.
    Kawada J; Torii Y; Kawano Y; Suzuki M; Kamiya Y; Kotani T; Kikkawa F; Kimura H; Ito Y
    J Clin Virol; 2015 Apr; 65():41-5. PubMed ID: 25766986
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sequential treatment of cytomegalovirus infection or disease with a short course of intravenous ganciclovir followed by oral valganciclovir: efficacy, safety, and pharmacokinetics.
    Caldés A; Gil-Vernet S; Armendariz Y; Colom H; Pou L; Niubó J; Lladó L; Torras J; Manito N; Rufí G; Grinyó JM
    Transpl Infect Dis; 2010 Jun; 12(3):204-12. PubMed ID: 20002612
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Valganciclovir as pre-emptive therapy for cytomegalovirus infection post-allogenic stem cell transplantation: implications for the emergence of drug-resistant cytomegalovirus.
    Allice T; Busca A; Locatelli F; Falda M; Pittaluga F; Ghisetti V
    J Antimicrob Chemother; 2009 Mar; 63(3):600-8. PubMed ID: 19147520
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Resistance pattern of cytomegalovirus (CMV) after oral valganciclovir therapy in transplant recipients at high-risk for CMV infection.
    Boutolleau D; Deback C; Bressollette-Bodin C; Varnous S; Dhedin N; Barrou B; Vernant JP; Gandjbakhch I; Imbert-Marcille BM; Agut H
    Antiviral Res; 2009 Feb; 81(2):174-9. PubMed ID: 19063923
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cytomegalovirus UL97 mutations associated with ganciclovir resistance in immunocompromised patients from Argentina.
    Sánchez Puch S; Ochoa C; Carballal G; Zala C; Cahn P; Brunet R; Salomón H; Videla C
    J Clin Virol; 2004 Jul; 30(3):271-5. PubMed ID: 15135748
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Repopulation of ganciclovir-resistant cytomegalovirus by wild-type virus.
    Drew WL; Liu C
    Clin Transplant; 2012; 26(6):949-52. PubMed ID: 22774759
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment of symptomatic congenital cytomegalovirus infection with intravenous ganciclovir followed by long-term oral valganciclovir.
    Amir J; Wolf DG; Levy I
    Eur J Pediatr; 2010 Sep; 169(9):1061-7. PubMed ID: 20232081
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ganciclovir-resistant cytomegalovirus infection in solid organ transplant recipients: a single-center retrospective cohort study.
    Young PG; Rubin J; Angarone M; Flaherty J; Penugonda S; Stosor V; Ison MG
    Transpl Infect Dis; 2016 Jun; 18(3):390-5. PubMed ID: 27037651
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Oral valganciclovir treatment in newborns with symptomatic congenital cytomegalovirus infection.
    Lombardi G; Garofoli F; Villani P; Tizzoni M; Angelini M; Cusato M; Bollani L; De Silvestri A; Regazzi M; Stronati M
    Eur J Clin Microbiol Infect Dis; 2009 Dec; 28(12):1465-70. PubMed ID: 19763643
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Development of new cytomegalovirus UL97 and DNA polymerase mutations conferring drug resistance after valganciclovir therapy in allogeneic stem cell recipients.
    Marfori JE; Exner MM; Marousek GI; Chou S; Drew WL
    J Clin Virol; 2007 Feb; 38(2):120-5. PubMed ID: 17157554
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Recurrent and persistent cytomegalovirus infection in a kidney recipient caused by the L595S mutation in UL97 phosphotransferase gene.
    Peixoto M; Mascarenhas L; Cunha A; Dutra M; Miranda E; Silva I; Costa S; Galvão B; Cunha A
    Antivir Ther; 2012; 17(3):585-8. PubMed ID: 22293247
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.